| 價(jià)格 | ¥769 |
| 包裝 | 10μg |
| 最小起訂量 | 10μg |
| 發(fā)貨地 | 上海 |
| 更新日期 | 2026-05-09 |
| 中文名稱:PHGDH, Human, 重組蛋白 (His) | 英文名稱:PHGDH Protein, Human, Recombinant (His) |
| 品牌: TargetMol | 產(chǎn)地: 美國(guó) |
| 保存條件: Store at low temperature Store at -80°C | 純度規(guī)格: 96.00% |
| 產(chǎn)品類別: 抑制劑 | |
| 種屬: Human | 表達(dá)系統(tǒng): E. coli |
| 蛋白長(zhǎng)度: A DNA sequence encoding the mature form of human PHGDH (O43175) (Met 1-Phe 533) was fused with a polyhistidine tag at the C-terminus and an initial Met at the N-terminus. Predicted N terminal: Met | 標(biāo)簽: C-His |
| 貨號(hào): T011|TMPY-02801 |
| 名稱 | PHGDH Protein, Human, Recombinant (His) |
| 描述 | PHGDH is a member of the D-isomer specific 2-hydroxyacid dehydrogenase family. This new family consists of D-isomer-stereospecific enzymes. The conserved residues in this family appear to be the residues involved in the substrate binding and the catalytic reaction, and thus to be targets for site-directed mutagenesis. A number of NAD-dependent 2-hydroxyacid dehydrogenases which seem to be specific for the D-isomer of their substrate have been shown to be functionally and structurally related. PHGDH catalyzes the transition of 3-phosphoglycerate into 3-phosphohydroxypyruvate, which is the first and rate-limiting step in the phosphorylated pathway of serine biosynthesis, using NAD+/NADH as a cofactor. Overexpression of PHGDH may cause certain breast cancers. Defects in PHGDH are the cause of phosphoglycerate dehydrogenase deficiency which is characterized by congenital microcephaly, psychomotor retardation, and seizures. |
| 存儲(chǔ)條件 | Store at low temperature Store at -80°C |
| 關(guān)鍵字 | NLS-1 | NLS 1 | HEL-S113 | HEL-S 113 |
| 成立日期 | 2013-04-18 (14年) | 注冊(cè)資本 | 589.8595萬人民幣 |
| 員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
| 主營(yíng)行業(yè) | 天然產(chǎn)物,生物化工,化學(xué)試劑,生物技術(shù)服務(wù) | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
| 產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
|---|---|---|---|---|
| ¥1788 |
VIP2年
|
普健生物(武漢)科技有限公司
|
2026-07-29 | |
| ¥3870 |
VIP2年
|
上海西格生物科技有限公司
|
2026-07-31 | |
| ¥3300 |
VIP1年
|
上海撫生實(shí)業(yè)有限公司
|
2026-07-31 |